Predictive value of 18F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: A preclinical study

Radiotherapy and Oncology

Volumn 114, Issue 2, 2015, Pages 189-194

  Tran, Ly Binh An ^a   Bol, Anne ^a   Labar, Daniel ^a   Cao Pham, Thanh Trang ^a   Jordan, Bénédicte ^a   Grégoire, Vincent ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

18F FAZA; Hypoxia; Nimorazole; Predictive marker; Radiotherapy

Indexed keywords

FLUOROAZOMYCIN ARABINOSIDE F 18; NIMORAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FLUORINE; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CONTROLLED STUDY; GLIOMA; HYPOXIA; MALE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RAT; RHABDOMYOSARCOMA; TREATMENT OUTCOME; ANIMAL; CELL HYPOXIA; CHEMORADIOTHERAPY; DIAGNOSTIC USE; DISEASE MODEL; FISCHER 344 RAT; PHYSIOLOGY; PROCEDURES; RANDOMIZATION; SCINTISCANNING;

ANIMALS; CELL HYPOXIA; CHEMORADIOTHERAPY; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; GLIOMA; MALE; NIMORAZOLE; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; RATS; RATS, INBRED F344; RHABDOMYOSARCOMA;

EID: 84926143930     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.12.015     Document Type: Article

References (35)

1. P. Vaupel, and A. Mayer Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 2007 225 239
2. C. Menon, and D.L. Fraker Tumor oxygenation status as a prognostic marker Cancer Lett 221 2005 225 235
3. T.H. Knocke, H.D. Weitmann, H.J. Feldmann, E. Selzer, and R. Potter Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix Radiother Oncol 53 1999 99 104
4. L.H. Gray, A.D. Conger, M. Ebert, S. Hornsey, and O.C.A. Scott The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br J Radiol 26 1953 638 648
5. L.B. Harrison, M. Chadha, R.J. Hill, K. Hu, and D. Shasha Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 2002 492 508
6. M. Nordsmark, S.M. Bentzen, and V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study Radiother Oncol 77 2005 18 24
7. J. Bernier, J. Denekamp, and A. Rojas ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC) Radiother Oncol 55 2000 111 119
8. P. Danhier, C.J. De Saedeleer, and O. Karroum Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications Semin Radiat Oncol 23 2013 262 272
9. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
10. J.M. Henk, K. Bishop, and S.F. Shepherd Treatment of head and neck cancer with CHART and nimorazole: phase II study Radiother Oncol 66 2003 65 70
11. J. Overgaard, H.S. Hansen, and M. Overgaard A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Radiother Oncol 46 1998 135 146
12. J. Overgaard Hypoxic radiosensitization: adored and ignored J Clin Oncol 25 2007 4066 4074
13. M.R. Horsman, L.S. Mortensen, J.B. Petersen, M. Busk, and J. Overgaard Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 9 2012 674 687
14. A. Yaromina, M. Krause, and M. Baumann Individualization of cancer treatment from radiotherapy perspective Mol Oncol 6 2012 211 221
15. 18F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy Radiother Oncol 113 2014 204 209
16. W. Landuyt, B. Ahmed, and S. Nuyts In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment Int J Radiat Oncol Biol Phys 49 2001 443 450
17. 18F]FAZA: reaction parameters and automation Appl Radiat Isot 62 2005 897 901
18. J. Overgaard, M. Overgaard, O.S. Nielsen, A.K. Pedersen, and A.R. Timothy A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo Br J Cancer 46 1982 904 911
19. C. Sugie, Y. Shibamoto, and M. Ito Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo J Radiat Res 46 2005 453 459
20. J.H. Kaanders, K.I. Wijffels, and H.A. Marres Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
21. J. Bussink, J.H. Kaanders, and P.F. Rijken Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide Radiother Oncol 50 1999 173 184
22. A.L. Grosu, M. Souvatzoglu, and B. Röper Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 2007 541 551
23. 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients J Nucl Med 54 2013 1175 1180
24. L.S. Mortensen, M. Busk, and M. Nordsmark Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study Radiother Oncol 99 2011 418 423
25. L.S. Mortensen, J. Johansen, and J. Kallehauge FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
26. K. Toustrup, B.S. Sørensen, and P. Lassen Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck Radiother Oncol 102 2012 122 129
27. J. Overgaard, J.G. Eriksen, and M. Nordsmark Plasma osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial Lancet Oncol 6 2005 757 764
28. P. Wardman Chemical radiosensitizers for use in radiotherapy Clin Oncol 19 2007 397 417
29. 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry Radiother Oncol 105 2012 29 35
30. C.M. Doll, M. Milosevic, M. Pintilie, R.P. Hill, and A.W. Fyles Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients Int J Radiat Oncol Biol Phys 55 2003 1239 1246
31. J. Dunst, P. Stadler, and A. Becker Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important Strahlenther Onkol 179 2003 521 526
32. M. Saunders, and S. Dische Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide Br J Cancer Suppl 27 1996 S271 S278
33. L.J. Peters The ESTRO Regaud Lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response Radiother Oncol 17 1990 177 190
34. M. Baumann, W. Dorr, C. Petersen, and M. Krause Repopulation during fractionated radiotherapy: much has been learned, even more is open Int J Radiat Biol 79 2003 465 467
35. P. Bhatnagar, M. Subesinghe, C. Patel, R. Prestwich, and A.F. Scarsbrook Functional imaging for radiation treatment planning, response assessment, and adaptive therapy in head and neck cancer RadioGraphics 33 2013 1909 1929